Area of research
Oncology · Molecular Biology
Research interest
Research focused on Human serum albumin and Cytotoxicity, with related work in Photocatalysis, In vivo, Degradation (telecommunications). Notable publications include 'Rapid synthesis of Ag/AgCl@ZIF-8 as a highly efficient photocatalyst for degradation of acetaminophen under visible light', 'Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain', and 'Revealing the Relationship between Photocatalytic Properties and Structure Characteristics of TiO 2 Reduced by Hydrogen and Carbon Monoxide Treatment'.
Oxoisoaporphine Alkaloid Iridium(III) Derivative: An Immunogenic Cell Death Inducer That Engages the Autophagy-Dependent Regulator Cathepsin D
Design of a theranostic Gd (III)–Cu (I) complex to inhibit growth and metastasis of triple‐negative breast cancer
Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated Hypercholesterolemia
Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response
Rapid synthesis of Ag/AgCl@ZIF-8 as a highly efficient photocatalyst for degradation of acetaminophen under visible light
Revealing the Relationship between Photocatalytic Properties and Structure Characteristics of TiO<sub>2</sub> Reduced by Hydrogen and Carbon Monoxide Treatment
Growth inhibition of<i>Microcystic aeruginosa</i>by metal–organic frameworks: effect of variety, metal ion and organic ligand
Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin
HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model
Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents
Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism
Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer
Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain
Structural Basis of Non‐Steroidal Anti‐Inflammatory Drug Diclofenac Binding to Human Serum Albumin